Apolipoprotein E abundance is elevated in the brains of individuals with Down syndrome–Alzheimer’s disease

• Published in: Acta neuropathologica Vol. 149; no. 1; p. 49
• Main Authors: Farrell, Clíona, Buhidma, Yazead, Mumford, Paige, Heywood, Wendy E., Hällqvist, Jenny, Flores-Aguilar, Lisi, Andrews, Elizabeth J., Rahimzadah, Negin, Taso, Orjona Stella, Doran, Eric, Swarup, Vivek, Head, Elizabeth, Lashley, Tammaryn, Mills, Kevin, Toomey, Christina E., Wiseman, Frances K.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 19.05.2025; Springer Nature B.V
• Subjects: Adult; Alzheimer Disease - genetics; Alzheimer Disease - metabolism; Alzheimer Disease - pathology; Alzheimer's disease; Apolipoprotein E; Apolipoproteins E - genetics; Apolipoproteins E - metabolism; Astrocytes; Brain - metabolism; Brain - pathology; Case-Control Studies; Chromosome 21; Chromosomes, Human, Pair 21 - genetics; Cortex (frontal); Dementia disorders; Down syndrome; Down Syndrome - complications; Down Syndrome - genetics; Down Syndrome - metabolism; Down Syndrome - pathology; Down's syndrome; Endothelial cells; Female; Healthy Aging - genetics; Humans; Male; Medicine; Medicine & Public Health; Middle Aged; Neurodegenerative diseases; Neurosciences; Original Paper; Pathology; Pericytes; Proteome - genetics; Proteomes; Single-Cell Gene Expression Analysis; Transcriptome - genetics; Transcriptomes; Trisomy; Trisomy 21; APOE; Frontal cortex; Neuropathology; Mass spectrometry; Amyloid precursor protein
• ISSN: 1432-0533; 0001-6322; 1432-0533
• DOI: 10.1007/s00401-025-02889-0

Trisomy of chromosome 21, the cause of Down syndrome (DS), is the most commonly occurring genetic cause of Alzheimer’s disease (AD). Here, we compare the frontal cortex proteome of people with Down syndrome–Alzheimer’s disease (DSAD) to demographically matched cases of early onset AD and healthy ageing controls. We find dysregulation of the proteome, beyond proteins encoded by chromosome 21, including an increase in the abundance of the key AD-associated protein, APOE, in people with DSAD compared to matched cases of AD. To understand the cell types that may contribute to changes in protein abundance, we undertook a matched single-nuclei RNA-sequencing study, which demonstrated that APOE expression was elevated in subtypes of astrocytes, endothelial cells, and pericytes in DSAD. We further investigate how trisomy 21 may cause increased APOE. Increased abundance of APOE may impact the development of, or response to, AD pathology in the brain of people with DSAD, altering disease mechanisms with clinical implications. Overall, these data highlight that trisomy 21 alters both the transcriptome and proteome of people with DS in the context of AD, and that these differences should be considered when selecting therapeutic strategies for this vulnerable group of individuals who have high risk of early onset dementia.